-
Product Insights
Serine/Threonine Protein Kinase Pim – Drugs In Development, 2023
Global Markets Direct’s Serine/Threonine Protein Kinase Pim provides in depth analysis on Serine/Threonine Protein Kinase Pim targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase...
-
Product Insights
Serine/Threonine Protein Kinase Pim 1 – Drugs In Development, 2023
Global Markets Direct’s Serine/Threonine Protein Kinase Pim 1 provides in depth analysis on Serine/Threonine Protein Kinase Pim 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine...
-
Product Insights
Serine/Threonine Protein Kinase Pim 3 – Drugs In Development, 2023
Global Markets Direct’s Serine/Threonine Protein Kinase Pim 3 provides in depth analysis on Serine/Threonine Protein Kinase Pim 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine...
-
Product Insights
Serine/Threonine Protein Kinase Pim 2 – Drugs In Development, 2023
Global Markets Direct’s Serine/Threonine Protein Kinase Pim 2 provides in depth analysis on Serine/Threonine Protein Kinase Pim 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TP-3654 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TP-3654 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TP-3654 in Triple-Negative Breast Cancer (TNBC) Drug Details: TP-3654 (SGI-9481)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Refractory Acute Myeloid Leukemia Drug Details: MEN-1703 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Relapsed Acute Myeloid Leukemia Drug Details: MEN-1703 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JTV-161 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JTV-161 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JTV-161 in Pulmonary Arterial HypertensionDrug Details:JTV-161 is under the development for the...